BioSig Reports Exit Costs, Officer Changes on Jan 28
Ticker: STEX · Form: 8-K · Filed: Feb 1, 2024 · CIK: 1530766
| Field | Detail |
|---|---|
| Company | Biosig Technologies, Inc. (STEX) |
| Form Type | 8-K |
| Filed Date | Feb 1, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $138,667, $48,533, $919,249, $205,325 |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: restructuring, management-change, corporate-action
TL;DR
**BioSig 8-K hints at restructuring and leadership shake-up, watch for details.**
AI Summary
BioSig Technologies, Inc. filed an 8-K on February 1, 2024, reporting events from January 28, 2024. The filing indicates "Cost Associated with Exit or Disposal Activities" and "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers." This suggests potential restructuring or leadership changes, which could impact the company's strategic direction and financial performance, making it important for investors to monitor for further details on these activities.
Why It Matters
This filing signals potential operational shifts and leadership adjustments at BioSig Technologies, Inc., which could influence future financial stability and strategic direction. Investors should watch for subsequent disclosures to understand the full scope and impact of these changes.
Risk Assessment
Risk Level: medium — The filing indicates significant events like 'Cost Associated with Exit or Disposal Activities' and 'Departure of Directors or Certain Officers,' which introduce uncertainty about the company's future operations and leadership stability.
Analyst Insight
A smart investor would monitor BioSig Technologies, Inc. for subsequent filings that provide specific details on the 'Exit or Disposal Activities' and the identities of the departing and newly appointed officers, as these events could significantly impact the company's future strategy and financial health.
Key Numbers
- January 28, 2024 — Date of earliest event reported (Indicates when the reported events, such as exit activities and officer changes, occurred.)
- February 1, 2024 — Filing Date (The date the 8-K was officially filed with the SEC.)
- $0.001 — Par value per share (The stated par value of BioSig Technologies, Inc.'s Common Stock.)
Key Players & Entities
- BioSig Technologies, Inc. (company) — registrant
- January 28, 2024 (date) — date of earliest event reported
- February 1, 2024 (date) — filing date
- Delaware (company) — state of incorporation for BioSig Technologies, Inc.
- 001-38659 (dollar_amount) — Commission File Number
- 26-4333375 (dollar_amount) — IRS Employer Identification No.
- $0.001 (dollar_amount) — par value per share of Common Stock
Forward-Looking Statements
- BioSig Technologies, Inc. will provide more specific details regarding the 'Exit or Disposal Activities' in a future filing. (BioSig Technologies, Inc.) — medium confidence, target: Q1 2024
- The company will announce the names of the departing and newly appointed officers. (BioSig Technologies, Inc.) — high confidence, target: Q1 2024
FAQ
What specific events did BioSig Technologies, Inc. report in this 8-K filing?
BioSig Technologies, Inc. reported 'Cost Associated with Exit or Disposal Activities' and 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' as events occurring on January 28, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 28, 2024.
What is the par value of BioSig Technologies, Inc.'s Common Stock?
The par value of BioSig Technologies, Inc.'s Common Stock is $0.001 per share.
What is the Commission File Number for BioSig Technologies, Inc.?
The Commission File Number for BioSig Technologies, Inc. is 001-38659.
Where is BioSig Technologies, Inc.'s principal executive office located?
BioSig Technologies, Inc.'s principal executive office is located at 55 Greens Farms Road, 1st Floor, Westport, Connecticut, 06880.
Filing Stats: 1,026 words · 4 min read · ~3 pages · Grade level 13 · Accepted 2024-02-01 17:25:12
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital M
- $138,667 — Company as a consultant for a total of $138,667, paid in equity, over a four-month peri
- $48,533 — Company as a consultant for a total of $48,533, paid in equity, over a two-month perio
- $919,249 — total aggregate costs of approximately $919,249, which consists of: payments for consul
- $205,325 — id in equity in the estimated amount of $205,325; one-time departure fees and severance
- $135,288 — employment, in the estimated amount of $135,288; and retention bonuses paid in equity i
- $578,636 — id in equity in the estimated amount of $578,636. These estimates are subject to a numbe
- $30,000 — ncluding estimated cash expenditures of $30,000. Item 5.02 Departure of Directors or
Filing Documents
- form8-k.htm (8-K) — 49KB
- ex10-1.htm (EX-10.1) — 92KB
- 0001493152-24-004629.txt ( ) — 330KB
- bsgm-20240128.xsd (EX-101.SCH) — 3KB
- bsgm-20240128_lab.xml (EX-101.LAB) — 33KB
- bsgm-20240128_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Consulting Agreement, dated January 31, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOSIG TECHNOLOGIES, INC. Date: February 1, 2024 By: /s/ Kenneth L. Londoner Name: Kenneth L. Londoner Title: Executive Chairman